去勢抵抗性前立腺がんにおけるアンドロゲン受容体核移行阻害に関する研究 by 石倉 信之 & ISHIKURA Nobuyuki
Studies on the Inhibition of Androgen Receptor
Nuclear Translocation in the
Castration-resistant Prostate Cancer Cells
著者 石倉 信之
year 2017
その他のタイトル 去勢抵抗性前立腺がんにおけるアンドロゲン受容体
核移行阻害に関する研究
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2016
報告番号 12102甲第8123号
URL http://hdl.handle.net/2241/00147661
Studies on the Inhibition of Androgen Receptor 
Nuclear Translocation 
in the Castration-resistant Prostate Cancer Cells 
A Dissertation Submitted to 
the Graduate School of Life and Environmental Sciences, 
the University of Tsukuba 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy in Biological Science 
( Doctoral Program in Biological Sciences ) 
Nobuyuki ISHIKURA 
 
 
Contents 
 
 
 
Abstract         1 
General introduction        3 
 
 
Chapter I. Establishment and characterization of an AR-dependent, 
androgen-independent human prostate cancer cell line, LNCaP-CS10 
 
Introduction         7 
Materials and methods       8 
Results        11 
Discussion        14 
 
 
Chapter II. Significance of AR nuclear translocation in castration-resistant 
prostate cancer cells 
 
Introduction        18 
Materials and methods      20 
Results        25 
Discussion        29 
 
 
General Discussion       33 
Acknowledgements       36 
References        37 
Table         44 
Figures          46
1 
 
Abstract 
 
Castration resistance is a lethal problem for advanced prostate cancer patients. The 
major mechanisms of such resistance are androgen receptor (AR) overexpression, AR 
mutation, and androgen-independent activation of AR. The aim of the present study was 
to examine the influence of inhibiting AR nuclear transfer, a process common to these 
three major mechanisms. First, I established a castration-resistant prostate cancer 
(CRPC) cell line with androgen-independent activation of AR, which is the first such 
cell model for studying this mechanism that has been proposed but not yet 
experimentally proven. LNCaP-CS10 was established from a hormone-sensitive 
prostate cancer (HSPC) cell line, LNCaP, by treatment under an androgen-depleted 
condition with 10 µM bicalutamide. Compared to LNCaP cells, LNCaP-CS10 cells did 
not show AR overexpression or any additional AR mutation. LNCaP-CS10 cells 
exhibited an increase in proliferation and prostate-specific antigen (PSA) production in 
the absence of androgen, and induction of these phenomena was observed following 
treatment with bicalutamide. In the absence of androgen, AR knockdown suppressed 
LNCaP-CS10 proliferation and PSA production. AR nuclear translocation was induced 
by bicalutamide treatment to LNCaP-CS10 cells. The growth and PSA production of 
xenografted LNCaP-CS10 tumors were not inhibited by castration or administration of 
bicalutamide. Next, to examine the influence of inhibiting AR nuclear transfer, I used an 
AR nuclear translocation-inhibiting compound, CH5137291, which my coworkers and I 
developed recently, and compared its activity and characteristics with those of 
bicalutamide. I analyzed three cell lines corresponding to the three mechanisms of 
castration resistance: LNCaP-BC2, showing AR overexpression; PC3, harboring mutant 
AR through transient transfection; and LNCaP-CS1, showing androgen-independent AR 
activation. Two other cell lines, VCaP and LNCaP, were also used as HSPC cells. An in 
vitro intracellular localization assay showed that CH5137291 inhibited the nuclear 
translocation of wild-type ARs as well as W741C and T877A mutant ARs. In addition, 
CH5137291 exhibited a complete AR antagonist effect without an AR agonist effect on 
the transcriptional activity of these types of ARs. In contrast, bicalutamide did not 
inhibit the nuclear translocation of these ARs, and showed a partial or full agonist effect 
on transcriptional activity. CH5137291 inhibited cell growth more strongly than 
bicalutamide in VCaP and LNCaP cells as well as in LNCaP-BC2 and LNCaP-CS10 
cells in vitro. In xenograft models, CH5137291 strongly inhibited the tumor growth of 
LNCaP, LNCaP-BC2, and LNCaP-CS10 cells, whereas bicalutamide showed a weaker 
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effect on LNCaP and almost no effect on LNCaP-BC2 and LNCaP-CS10 xenografts. 
The plasma levels of PSA correlated well with the antitumor effect of both agents. 
CH5137291 inhibited the growth of LNCaP tumors that had become resistant to 
bicalutamide treatment. A docking model suggested that CH5137291 intensively 
collided with the M895 residue of helix 12, and therefore strongly inhibited the folding 
of helix 12, a cause of AR agonist activity, in wild-type and W741C-mutant ARs. In 
normal cynomolgus monkeys, the serum concentration of CH5137291 increased 
dose-dependently and the PSA level decreased by 80% when CH5137291 dose was 100 
mg/kg. Overall, in the present study, I clearly demonstrated that castration resistance 
could be acquired by androgen-independent AR activation as well as by AR 
overexpression or AR mutation, and that inhibition of AR nuclear translocation could 
offer a novel therapeutic approach against the major types of CRPCs and prolong the 
response duration against HSPC. 
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General introduction 
 
Prostate cancer is the most common epithelial cancer and the second leading cause of 
cancer-related deaths in males in the United States (1-5). Because most prostate cancers 
are initially dependent on androgens for their growth, patients with prostate cancer 
receive androgen depletion therapies. Existing androgen depletion therapies are initially 
effective for most patients against this disease (6,7). At this time, prostate cancer is 
referred to as hormone-sensitive prostate cancer (HSPC). However, the cancer often 
acquires resistance and becomes refractory to these therapies in several years 
(castration-resistant prostate cancer, CRPC), which is a major clinical challenge (8,9). 
Because the expression of prostate-specific antigen (PSA), a target gene of androgen 
receptor (AR) and a tumor marker reflecting the proliferation of prostate cancer, is 
observed in the majority of CRPC cases, the AR-dependent growth signal is thought to 
remain in CRPC (8-10). Once HSPC becomes CRPC, there are few effective treatments, 
and thus novel treatment methods are required. 
Androgen refers to all male hormones, including testosterone. Testosterone is mainly 
synthesized in the testis and partly in the adrenal gland, which account for 
approximately 95% and 5% of total androgen, respectively. AR has very high sequence 
similarity with other nuclear receptors (e.g., progesterone receptor, PR; glucocorticoid 
receptor, GR; mineralocorticoid receptor, MR; and estrogen receptors, ERs) belonging 
to the nuclear receptor superfamily. Steroid hormone receptors belonging to the nuclear 
receptor superfamily generally consist of three structural units: AF-1, which is a 
ligand-independent transcriptional activation region at the N-terminus; a DNA-binding 
domain; and AF-2, which contains a ligand-binding domain and exists at the C-terminus 
showing ligand-dependent transcriptional activity (6). Helix 12 of AR takes on a 
three-dimensional structure like a lid in a pocket-like space to which a ligand binds. In 
the unliganded state, AR exhibits an unfolded structure such that the lid is opened, and 
when the ligand is bound, helix 12 takes on a folded structure in which the lid is closed. 
The androgen antagonists bind to the ligand-binding domain competitively with the 
ligand, thereby interfering with the folding the helix 12 and ultimately inhibiting 
transcriptional activity (11,12). 
Here, I will provide a brief overview of the AR signal, which is the key to prostate 
cancer proliferation. Testosterone secreted from the testis and adrenal glands is 
metabolized to dihydroxytestosterone (DHT), activated androgen, by 5α reductase in 
prostate cancer cells (13). Testosterone secretion from the testis occurs through 
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stimulation of luteinizing hormone-releasing hormone (LH-RH) from the hypothalamus 
and luteinizing hormone (LH) from the pituitary gland. AR, to which DHT binds as a 
ligand, forms a dimer, transitions from the cytoplasm to the nucleus, and shows 
transcriptional activity via binding to the androgen response element on DNA as a 
transcription factor (13,14). 
Androgen depletion therapies include surgical castration, treatment with an LH-RH 
agonist aimed at inhibiting testicular-derived androgen secretion, and treatment with an 
AR antagonist intended to inhibit the action of androgens (6,7). An agonist is a 
substance that binds to and activates the receptor, whereas an antagonist is a substance 
that binds to and inhibits the activity of the receptor. The LH-RH agonist inhibits the 
secretion of testosterone from the testes by decreasing the expression of the pituitary 
LH-RH receptor upon its continuous administration. However, this cannot suppress the 
secretion of androgen from the adrenal glands. Therefore, AR antagonists such as 
bicalutamide and flutamide, which inhibit the binding of androgen and AR, are used in 
combination with an LH-RH agonist (7). This combination therapy is called total 
androgen blockade (6,7). However, these therapies also cannot completely block the AR 
signal. Therefore, resistance is ultimately acquired in most patients (8).  
There are three main mechanisms of castration resistance reported thus far (13). The 
first mechanism is overexpression of AR, which increases the sensitivity to androgen, 
resulting in accelerated nuclear translocation of AR and proliferation even at androgen 
concentrations that are kept low by androgen depletion therapy and where proliferation 
is not observed in HSPC cells (15-17). The second mechanism is mutation of AR. 
Mutations in the ligand-binding domain of AR create loss of ligand specificity, so that 
anti-androgens act as agonists for the mutated ARs (18-22). In particular, the W741C 
and T877A mutant ARs are reported to be activated by bicalutamide and flutamide, 
respectively (22). Many models have been established for studying these two 
mechanisms, with extensive research conducted to date (15,17-19,21,22). The third 
mechanism is proposed as androgen-independent AR activation. However, there is no 
available model for studying this mechanism, and thus it has not yet been clearly proven. 
The frequency of the clinical occurrence of these three mechanisms is 25–30%, 10–30%, 
and ~30%, respectively. 
AR nuclear translocation is a common signaling pathway not only for HSPC but also 
for CRPC. Therefore, I hypothesized that inhibition of AR nuclear translocation would 
inhibit the proliferation of CRPC cells via the three resistance mechanisms described 
above. The aims of this study were (I) to establish a CRPC cell line with characteristics 
of androgen-independent AR activation, a model that had not been established when I 
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started this study (Chapter I); and (II) to examine the effect of inhibition of AR nuclear 
translocation, a common signaling pathway of CRPC, on CRPC cell lines with 
androgen-independent activation of AR, overexpression of AR, and with mutations in 
AR genes (Chapter II). 
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Chapter I. 
 
 
Establishment and characterization of  
an AR-dependent, androgen-independent  
human prostate cancer cell line, LNCaP-CS10 
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Introduction 
 
Recent analysis revealed that expression of AR remained in most castration-resistant 
prostate cancer (CRPC) specimens and these patients were still PSA positive (8-10). 
These observations suggest that the AR signal is still active in castration-resistant 
prostate cancer cells, and therefore AR is a potential therapeutic target for 
castration-resistant prostate cancer.   
In a recent review, Pienta et al. (Fig. 1) (13) suggested three major mechanisms of 
androgen refractoriness: i) overexpression of AR, ii) mutations in AR genes and iii) 
androgen-independent activation of AR. AR overexpression leads to hypersensitivity to 
very low levels of androgen in patients treated with hormonal therapies (15-17). 
Mutations in the ligand-binding domain of AR create loss of ligand specificity and so 
anti-androgens act as agonists for the mutated ARs (18-22). The androgen-refractory 
cells with androgen-independent activation of AR are termed “outlaw”. In outlaw 
tumors, ARs are activated by androgen-independent pathways, such as deregulated 
cytokines and growth factors, including IL-6, IGF and EGF (23-29).  
Although several castration-resistant prostate cancer cell lines with AR 
overexpression or AR mutation have been established, no castration-resistant prostate 
cancer cell lines using the outlaw pathway have been established  (17,22,30-32). 
In this study, I isolated a novel bicalutamide-resistant and androgen-independent 
prostate cancer cell line (LNCaP-CS10) and demonstrated its outlaw pathway both in 
vitro and in vivo.  
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Material and methods 
 
Cell culture 
The androgen-dependent human prostate cancer cell line LNCaP was obtained from the 
American Type Culture Collection (Manassas, VA, USA) and maintained in 10% FCS 
medium consisting of RPMI1640 (Sigma, St. Louis, MO, USA) and 10% FCS (Japan 
Bioserum, Hiroshima, Japan) at 37°C in 5% CO2. The LNCaP-CS10 cells were 
maintained in 10% DCC medium consisting of phenol red-free RPMI1640 (Invitrogen, 
Carlsbad, CA, USA) and 10% charcoal/dextran-treated FCS (DCC-FCS) (Hyclone 
Laboratories, Logan, UT, USA) in the presence of 10 μM bicalutamide. 
 
Cell proliferation assays 
Androgen depleted cells were prepared by preincubation in 10% DCC medium for 3 
days and the cells were then plated onto a 96-well poly-D-lysine coated plate (Beckton 
Dickinson, Franklin Lakes, NJ, USA) at 1 × 104 cells/well (LNCaP) or 5 × 103 
cells/well (LNCaP-CS10) in 10% DCC medium. After overnight incubation at 37°C in 
5% CO2, R1881 (NEN Life Science, Boston, MA, USA) or bicalutamide was added. 
After a further 9 days of incubation at 37°C in 5% CO2, the number of cells remaining 
was counted by DNA quantity assay (FluoReporter Blue Fluorometric dsDNA 
Quantitation Kit; Invitrogen).  
 
Quantification of cellular PSA 
After androgen depletion for 3 days, the cells were plated onto a 24-well poly-D-lysine 
coated plate (Beckton Dickinson) at 2 × 105 cells/well in 10% DCC medium, incubated 
overnight and R1881 or bicalutamide were added. After 2 days of incubation, the cells 
were lysed with ice-chilled 1× cell lysis buffer (Cell Signaling) supplemented with 
Complete Protease Inhibitor Cocktail Tablets (Roche Diagnostics, Basel, Swiss). After 
centrifugation at 14000 rpm for 10 min at 4ºC, PSA in the supernatant was quantified 
using PSA ELISA assay (E-plate Eiken PSA; Eiken Chemical, Tokyo, Japan). 
 
Knock-down experiments with AR siRNA 
LNCaP and LNCaP-CS10 cells were transfected with AR siRNA (Santa Cruz 
Biotechnology) or scramble siRNA (Invitrogen) using Hyperfect (Qiagen, Hilden, 
Germany) and then plated onto a 96-well poly-D-lysine coated plate at 5 × 103 
cells/well in 10% FCS medium (LNCaP) or 10% DCC medium (LNCaP-CS10), 
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respectively. At 6 h, 3 days and 6 days post-transfection, the cell counts were quantified 
as described above. In order to confirm AR knock-down in the transfected cells, the 
cells were plated onto a 24-well poly-D-lysine coated plate at 4 × 104 cells/well; 
intracellular PSA and AR were quantified by AR ELISA assay (Active Motif, Carlsbad, 
CA, USA) after 3 days. 
 
Preparation of nuclear, cytoplasmic and total fractions  
Cells were plated onto 6-well poly-D-lysine coated plates (Beckton Dickinson) at 3 × 
105 cells/well in 10% DCC medium. After 3 days of incubation, 10 μM bicalutamide 
was added and the plates were incubated for another 24 h. Then nuclear and 
cytoplasmic fractions were prepared using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA). Total fraction was 
prepared as described above. AR was detected by western blot analysis using antibody 
to AR (N-20; Santa Cruz Biotechnology) and an ECL+ western blotting analysis system 
(Amersham, Little Chalfont, UK). Immunodetections of c-Jun and IκBα (H-79 and C-15, 
respectively; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the 
loading control of nuclear and cytoplasmic/total fraction. 
 
Animal experiments 
Five-week-old male C.B-17/Icr-scid Jcl severe combined immune-deficient (SCID) 
mice purchased from CLEA Japan (Tokyo, Japan) were maintained on a 12/12 hour 
light/dark cycle (lights on at 7 a.m.) with constant temperature (20–26°C) and humidity 
(35–75%). Food and water were available ad libitum. The health of the animals was 
monitored by daily observation. The protocols of the animal studies were reviewed and 
approved by the Institutional Animal Care and Use Committee of Chugai 
Pharmaceutical Co., Ltd., and all animal experiments were performed in accordance 
with the Guidelines for the Accommodation and Care of Laboratory Animals 
promulgated in Chugai Pharmaceutical Co., Ltd. For xenograft experiments, 2 × 106 
cells of LNCaP or LNCaP-CS10 were subcutaneously inoculated with 50% phenol 
red-free Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) into the flank region of 
intact or surgically castrated mice. The tumor size was measured by caliper and 
expressed as cubic millimeters using the formula 0.5 × length × width2. Tumorigenicity 
was evaluated according to the number of mice bearing palpable tumors (>50mm3). 
Sensitivity of LNCaP or LNCaP-CS10 xenograft models to bicalutamide was evaluated 
as tumor growth inhibition. When the tumor size reached 110–370 mm3 (LNCaP) or 
90–270 mm3 (LNCaP-CS10), the animals were randomized and orally administered 
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either bicalutamide (10 or 100 mg/kg) or the drug vehicle (5% gum arabic). The drug 
was administered in 4–5 cycles of 5 days on, 2 days off, and tumor size and plasma PSA 
levels were measured at the designated time points.  
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Results 
 
Establishment of the androgen-independent, bicalutamide-resistant LNCaP-CS10 
cell line. 
To establish a total androgen blockade therapy-resistant prostate cancer cell line with 
outlaw pathway activation, LNCaP cells were incubated in 10% DCC medium in the 
presence of 10 μM bicalutamide. After a 4-month incubation, the surviving cells in the 
androgen-depleted media in the presence of bicalutamide were selected and designated 
as LNCaP-CS10.  
LNCaP-CS10 exhibited faster growth and higher PSA production in the 
androgen-depleted medium compared with LNCaP (4.9- and 8.3-fold, respectively, Fig. 
2A and B). The growth of LNCaP-CS10 in the androgen-depleted medium was 
comparable to that of parental LNCaP cells in the presence of 0.1 nM R1881. Although 
LNCaP-CS10 grew in an androgen-independent manner, R1881 treatment further 
stimulated the cell growth and PSA production of LNCaP-CS10 (Fig. 2A and B). 
Bicalutamide showed agonist activity and induced cell growth and PSA production in a 
dose-dependent manner in LNCaP-CS10 cells but did not stimulate growth or PSA 
production of LNCaP cells at any concentration (Fig. 2C and D).  
 
Characterization of the outlaw pathway of CS10 in vitro  
To confirm the outlaw mechanism of LNCaP-CS10, I first analyzed the sequence of AR 
cDNA in LNCaP-CS10 by a direct sequence method using PCR amplified AR cDNA. 
However, LNCaP-CS10 cells did not express a new alteration of AR sequence in 
comparison to LNCaP (data not shown). Next, I examined the level of AR expression 
and subcellular localization in LNCaP-CS10 cells and the effect from bicalutamide. AR 
protein expression in LNCaP-CS10 was similar to that in LNCaP (Fig. 2E). The 
bicalutamide treatment did not affect the total or cytoplasmic AR protein level in either 
LNCaP or LNCaP-CS10 cells (Fig. 2E, data not shown). On the other hand, the level of 
nuclear AR in the LNCaP-CS10 cells was increased by bicalutamide but not in the 
LNCaP cells (Fig. 2E).  
To examine the involvement of the AR signal on the androgen independence of 
LNCaP-CS10 cells, AR was suppressed with AR-specific siRNAs. The knockdown 
effect of these AR siRNAs was confirmed by measuring AR protein levels with ELISA 
(Fig. 3A and B). The siRNAs inhibited the growth and PSA production of LNCaP cells 
in the 10% FCS medium (Fig. 3C and E). And, in the androgen-depleted medium, the 
12 
 
AR siRNAs also inhibited the growth and PSA production of LNCaP-CS10 cells (Fig. 
3D and F).  
I examined the phosphorylation status of AKT and ERK and the protein level of 
IL-6Rα and performed a comparative genomic hybridization analysis and 
gene-expression profiling of in vitro-cultured LNCaP-CS10. No apparent differences 
between LNCaP-CS10 and LNCaP were observed for pAKT and pERK protein levels 
or copy number changes in PTEN genes, but overexpression of the IL-6Rα gene and 
protein were found in LNCaP-CS10 (data not shown). To investigate whether IL-6 axis 
activation plays a role in the mechanism of outlaw activation in LNCaP-CS10, I 
analyzed the effect of anti-IL-6 neutralizing antibody and anti-IL-6Rα neutralizing 
antibody on the growth of LNCaP-CS10 in the absence of androgen. I found that the 
cell growth of LNCaP-CS10 was not affected by anti-IL-6 antibody or anti-IL-6Rα 
antibody in the absence of androgen (data not shown). 
Lastly, to analyze the expression of downstream factors for AR signaling in 
LNCaP-CS10 cells, the levels of gene expression of cyclin-dependent kinase (CDK-1), 
CDK-2, CDK-4, cyclin A2 and cyclin B1 were examined. No apparent differences 
between LNCaP-CS10 and LNCaP were found for these factors (data not shown).  
 
Tumorigenicity and bicalutamide resistance of LNCaP-CS10 cells in castrated 
SCID mice.  
In order to confirm the outlaw mechanism of LNCaP-CS10 in vivo, I inoculated 
castrated and non-castrated SCID mice with LNCaP-CS10 and the parental LNCaP cells. 
In the LNCaP-CS10-inoculated mice, palpable tumors were detected in 90% (9/10) of 
non-castrated mice and 90% (9/10) of castrated mice 29 days after tumor inoculation 
(Fig. 4B). In contrast, palpable LNCaP tumors were detected in 80% (8/10) of 
non-castrated mice and no tumors were found in castrated mice 29 days after tumor 
inoculation (Fig. 4A). In addition, the growth rate of LNCaP-CS10 tumors was similar 
in both castrated and non-castrated mice, whereas the growth rate of LNCaP was lower 
in castrated mice than in non-castrated mice (Fig. 4C and D). 
To confirm the bicalutamide resistance of LNCaP-CS10 cells in vivo, I administered 
bicalutamide to the LNCaP-CS10 xenograft model in castrated SCID mice. The tumor 
growth of LNCaP-CS10 was not inhibited by 10 or 100 mg/kg bicalutamide in the 
castrated mice (Fig. 5B). The serum PSA level in LNCaP-CS10 tumors was slightly 
increased by the administration of 10 or 100 mg/kg bicalutamide (Fig. 5D). On the other 
hand, in non-castrated mice, the growth and the serum PSA level of parental LNCaP 
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were inhibited to a castration level by the administration of 10 or 100 mg/kg 
bicalutamide (Fig. 5A and C).  
 
 
 
14 
 
Discussion 
 
I have established an “outlaw” cell line, LNCaP-CS10 that is androgen-independent and 
AR-dependent from androgen-dependent LNCaP cells after a 4-month incubation in an 
androgen-depleted medium supplemented with bicalutamide. The androgen 
independence of LNCaP-CS10 was confirmed by its growth under androgen-depleted 
conditions. The parent LNCaP cell line showed no growth under the same conditions 
(Fig. 2A). Furthermore, LNCaP-CS10 produced PSA without androgen (Fig. 2B), 
indicating that the AR signal was still active.  
According to recent studies, the AR signal plays a pivotal role in a large segment of 
castration-resistant prostate cancers (8-10). The mechanisms of castration resistance 
include AR overexpression, AR mutation and ligand-independent activation of AR 
coined the outlaw pathway (13). To understand the mechanism for castration resistance 
of LNCaP-CS10, I analyzed the level of AR expression and the sequence of AR cDNA. 
LNCaP-CS10 did not show overexpression of AR or a new alteration of the AR 
sequence in comparison to LNCaP (Fig. 2E, data not shown). However, the experiments 
with AR siRNAs revealed outlaw activation that stimulated the growth and PSA 
production of LNCaP-CS10 cells (Fig. 3D and F).  
My tumorigenicity study results demonstrate that LNCaP-CS10 cells formed 
palpable tumors not only in non-castrated SCID mice but also in castrated SCID mice. 
The high tumor take rate and the ability to grow in castrated mice indicate that the 
LNCaP-CS10 cell line is suitable for evaluating new therapeutics for castration-resistant 
prostate cancer (Fig. 4B and D).   
To determine whether LNCaP-CS10 cells show bicalutamide resistance in vivo, I 
inoculated castrated SCID mice with LNCaP-CS10 cells. Growth and serum PSA level 
of LNCaP-CS10 tumors were not inhibited by 10 or 100 mg/kg bicalutamide, whereas 
tumor growth and the serum PSA level in LNCaP xenografts were suppressed by 10 or 
100 mg/kg bicalutamide (Fig. 5). I consider the reason why the LNCaP-CS10 tumor 
growth-inducing (agonist) activity of bicalutamide detected in the in vitro assay was not 
detected in this xenograft model to be the low level of adrenal gland-derived androgen 
remaining in the castrated mice. From these lines of evidence, LNCaP-CS10 was 
designated as an “outlaw” castration-resistant prostate cancer cell line.  
To investigate the mechanism of the resistance of LNCaP-CS10, I analyzed the 
effects of bicalutamide on growth and PSA production. To my surprise, bicalutamide 
induced the growth and PSA production of LNCaP-CS10 (Fig. 2C and D). The results 
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indicate that bicalutamide acted as an agonist in LNCaP-CS10 cells but not in LNCaP 
cells. Induction of nuclear AR by bicalutamide was more notable in LNCaP-CS10 cells 
than in LNCaP cells (Fig. 2E), although the total AR protein level was not increased in 
the cells. Bicalutamide is reported to translocate the transcriptionally inactive AR to the 
nuclei of LNCaP cells (14,33). But, the fact that bicalutamide acted as an agonist on 
growth and PSA production in LNCaP-CS10 suggests that the induction activity of 
bicalutamide on AR nuclear translocation contributed to the AR agonist activity of 
bicalutamide in LNCaP-CS10. 
Various mechanisms of castration resistance in outlaw tumors have been suggested 
such as activation of AR by deregulated cytokines and growth factors, including IL-6, 
IGF-1, EGF, KGF, through the JAK-STAT, Akt, MAPK pathways in the absence of 
androgen (27,34-38). To investigate the mechanism of outlaw activation in 
LNCaP-CS10, I first analyzed AKT and ERK status but found no apparent difference 
between LNCaP-CS10 and LNCaP for pAKT or pERK (data not shown). Next, the 
comparative genomic hybridization analysis did not reveal any of the copy number 
changes in the PTEN gene known to be the AKT pathway regulator and frequently 
deleted in prostate cancer cells (39,40). In addition, gene expression profiling and 
western blotting showed an overexpression of the IL-6Rα gene and protein in 
LNCaP-CS10. But the cell proliferation assay revealed that the anti-IL-6 neutralizing 
antibody and anti-IL-6Rα neutralizing antibody did not affect the growth of 
LNCaP-CS10 in the absence of androgen, indicating that IL-6 axis activation is not a 
mechanism of the outlaw activation of LNCaP-CS10 (data not shown).  
Lastly, I investigated the downstream of AR signaling in LNCaP-CS10 cells. The 
mitotic signaling of the AR is thought to ultimately target the cell cycle machinery (41). 
Androgen stimulates the expression of the cell cycle genes, cyclin-dependent kinase 1 
(CDK-1), CDK-2 and CDK-4, and increases the levels of cyclin A and cyclin B1 
mRNAs (42,43). Therefore, I analyzed the expression of androgen-regulated CDKs and 
cyclins using gene chip analysis under an androgen-depleted condition but found no 
apparent differences between LNCaP-CS10 and LNCaP for CDK-1, CDK-2, CDK-4, 
cyclin A2 and cyclin B1 (data not shown). Further study is necessary to elucidate the 
exact mechanism of the resistance of LNCaP-CS10. 
LNCaP-CS10 showed characteristics different from other bicalutamide-resistant cell 
lines previously reported. LNCaP-abl, which was derived from LNCaP and established 
after long-term culture in an androgen-depleted medium, showed AR overexpression 
and did not have a newly altered AR sequence (30). And LNCaP-abl cells showed 
hypersensitivity to androgen and induction by bicalutamide on cell growth. 
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LNCaP-CDXRs established in an androgen-depleted medium with 5 μM bicalutamide 
showed AR overexpression (31). LNCaP-CDXR cell growth was unaffected by 
bicalutamide but was repressed by androgen. LNCaP-BICs, established in an 
androgen-depleted medium with 10 pM R1881 and 1 μM bicalutamide for 3 months, 
did not show AR overexpression or alteration of the AR sequence, and its cell growth 
was unaffected by bicalutamide or R1881. Thus LNCaP-BICs were designated as AR 
by-pass models (44). On the other hand, LNCaP-CS10 did not show AR overexpression 
but cell growth was induced by both bicalutamide and R1881. KUCaP was established 
by transplanting liver metastatic tissue into male SCID mice (22). Tissue samples were 
obtained from a patient who was treated with total androgen blockade using 
bicalutamide. This cell line has W741C mutation in the ligand-binding domain of AR. 
LNCaP-cxDs established in an androgen-depleted medium with 1 μM or 0.1 μM 
bicalutamide have W741C or W741L mutation of AR in addition to the T877A 
mutation (32). In KUCaP and LNCaP-cxDs models, bicalutamide acts as an agonist as a 
result of the mutations. On the other hand, LNCaP-CS10 does not have these new 
mutations.   
In conclusion, I established a bicalutamide-resistant cell line, LNCaP-CS10, with 
outlaw pathway activation and is applicable to xenograft experiments. LNCaP-CS10 is 
useful for the elucidation of the outlaw pathway mechanisms of castration resistance 
and the evaluation of the efficacy of new therapeutics for castration-resistant prostate 
cancer.  
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Chapter II 
 
 
Significance of AR nuclear translocation  
in castration-resistant prostate cancer cells
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Introduction 
 
AR is a transcription factor that is known to be ligand-specifically activated. 
Unliganded AR, primarily located in the cytoplasm, translocates into the nucleus 
following androgen binding where it binds to specific DNA sequences and subsequently 
activates the transcription of its target genes (14). Expression of AR and 
prostate-specific antigen (PSA) persists in most CRPC specimens (8-10), suggesting 
that the AR signal remains obstinately active. Therefore, AR is still considered to be a 
potential therapeutic target for CRPC. Pienta et al. (13) proposed three major 
AR-related mechanisms of castration resistance (Fig. 1): i) hypersensitivity to androgen 
due to overexpression of AR (15-17); ii) loss of ligand specificity following an AR 
mutation (18-22); and iii) androgen-independent activation of AR mediated by 
deregulated growth factors and cytokines, termed “outlaw” activation (23-29). My 
collaborators and I have previously reported that existing AR antagonists, such as 
bicalutamide, have major limitations in that they have a so-called partial agonist profile 
(45,46). Specifically, those drugs have agonistic activity in addition to the intended 
antagonistic activity. Because of that, the drugs show no or at most weak antitumor 
effect against prostate cancers with castration resistance acquired by the three 
abovementioned mechanisms (32,46).  
It is well known that tamoxifen, an ERα antagonist widely used against breast 
cancers, also has a partial agonist profile and tumors can develop resistance to 
tamoxifen (47). To conquer the problem, ERα pure antagonists, such as fulvestrant 
(Faslodex), have been introduced and demonstrated to be efficacious against 
tamoxifen-resistant breast cancers (48-50). In an analogous fashion to ERα, I 
hypothesized that an AR antagonist without agonistic activity, namely an AR pure 
antagonist, would be efficacious against CRPC. 
Tran et al.  (51) reported a new compound effective against CRPC with 
AR-overexpression. The compound reduced the efficiency of AR nuclear translocation. 
However, the compound was reported to have a partial agonist activity and could not 
completely inhibit the translocation of AR into the nucleus. In light of those findings, 
and taking into account the successful experience with ERα pure antagonists, my 
coworkers and I screened approximately 2000 compounds for their properties as an AR 
nuclear translocation pure antagonist, and discovered a new compound, CH5137291, 
showing high-quality properties (52,53). 
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In the present study, I minutely examined the characteristics of CH5137291 as well 
as its antitumor activity in comparison with that of bicalutamide in several CRPC 
models with different mechanisms of resistance. In fact, I investigated the significance 
of AR nuclear translocation in CRPC which has the three major mechanisms, 
overexpression of AR, mutations in AR genes, and androgen-independent activation of 
AR. 
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Materials and Methods 
 
Reagents 
CH5137291 and fulvestrant were synthesized in my laboratories. Bicalutamide was 
purchased as Casodex tablets (AstraZeneca, London, UK) and purified in my 
laboratories. Synthetic androgen R1881 was purchased from NEN Life Science 
Products (Boston, MA, USA). Progesterone, mifepristone, dexamethasone, and 
β-estradiol were purchased from Sigma-Aldrich (St. Louis, MO, USA). Aldosterone 
was purchased from Acros Organics (Geel, Belgium). Abiraterone acetate was 
synthesized in my laboratories. 
 
Cells 
LNCaP, VCaP, PC3, HeLa, and COS-7 cells were obtained from the American Type 
Culture Collection (Manassas, VA, USA). LNCaP-BC2 and LNCaP-CS10 cells were 
previously established in my laboratory (46). LuCaP35V cells that progressed in 
castrated male mice and expressed wild-type AR were a gift from Prof. Robert L 
Vessella (University of Washington, Seattle, WA, USA) (54). LNCaP cells were 
maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 
10% FBS. VCaP cells were maintained in DMEM (high glucose) (Invitrogen) 
supplemented with 10% FBS. LNCaP-BC2 cells were maintained in phenol red-free 
RPMI-1640 supplemented with 10% FBS and 2 μM bicalutamide. LNCaP-CS10 cells 
were maintained in phenol red-free RPMI-1640 supplemented with 10% dextran-coated 
charcoal-treated FBS (DCC-FBS; Hyclone Laboratories, Logan, UT, USA) and 10 µM 
bicalutamide. PC3 cells were maintained in F-12 Kaighn’s medium (Invitrogen) 
supplemented with 10% FBS. HeLa cells were maintained in EMEM medium 
(Sigma-Aldrich) supplemented with 10% FBS, 1 mM sodium pyruvate (Invitrogen), 0.1 
mM nonessential amino acids (Invitrogen), and 1.5 g/L sodium bicarbonate 
(Sigma-Aldrich). COS-7 cells were maintained in DMEM (high glucose) supplemented 
with 10% FBS, 1.5 mM L-glutamine (Sigma-Aldrich), 4.5 g/L D-glucose 
(Sigma-Aldrich), and 1.5 g/L sodium bicarbonate. 
The characteristics in terms of hormone sensitivity, AR status, and AR mutation of 
these cell lines are summarized in Table I 
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Animals 
Five-week-old male C.B-17/Icr-scid Jcl severe combined immune-deficient (SCID) 
mice were purchased from CLEA Japan (Tokyo, Japan). Four- to 6-year-old 
cynomolgus monkeys (Macaca fascicularis) were bred in the Chugai Research Institute 
for Medical Science (Tokyo, Japan). All animals were housed in a pathogen-free 
environment under controlled conditions (temperature 20–26°C, humidity 35–75%, 
light/dark cycle 12/12 h). Chlorinated water and irradiated food were provided ad 
libitum. The health of the animals was monitored by daily observation. The protocols of 
the animal studies were reviewed and approved by the Institutional Animal Care and 
Use Committee of Chugai Pharmaceutical Co., Ltd., and all animal experiments were 
performed in accordance with the Guidelines for the Accommodation and Care of 
Laboratory Animals promulgated in Chugai Pharmaceutical Co., Ltd. 
 
Fluorescence imaging analysis 
LNCaP cells in 10% DCC-FBS medium were plated 24 h before transfection. To 
analyze intracellular translocation of AR, I used HaloTag system. The cells were 
transfected with HaloTag pHT2-hAR-WT, HaloTag pHT2-W741C, or HaloTag 
pHT2-T877A using Fugene HD transfection reagent (Roche, Basel, Switzerland). 
Forty-eight hours after the transfection, HaloTag TMR ligand (Promega, Fitchburg, WI, 
USA) was added, and the cells were incubated for 0.5 h. CH5137291 or bicalutamide 
(10 µM) was added in the presence or absence of R1881 (0.5 nM). After 2 h incubation, 
fluorescence imaging of the living cells was performed with a BioZero fluorescence 
microscope (Keyence, Osaka, Japan). 
 
Protein fractionation and western blotting 
Cells were plated onto poly-D-lysine coated plates (Becton Dickinson, Heidelberg, 
Germany) in 10% DCC-FBS medium. After 3-day incubation, 10 µM of CH5137291 or 
bicalutamide was added and the plates were incubated for another 24 h. Then, nuclear 
and cytoplasmic fractions were prepared by using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA), and a total fraction 
was prepared using cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) 
supplemented with Complete Protease Inhibitor Cocktail Tablets (Roche). AR-specific 
antibody N-20, IkBα-specific antibody C-15, and c-Jun-specific antibody H-79 (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) were used for immunoblotting. 
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Cell proliferation assay 
VCaP, LNCaP, LNCaP-BC2, and LNCaP-CS10 cells were pre-incubated in phenol 
red-free RPMI-1640 medium supplemented with 10% DCC-FBS for 2 to 4 days and 
were then plated onto poly-D-lysine-coated plates (Becton Dickinson) (VCaP, 1 × 104 
cells/well; LNCaP, LNCaP-BC2, and LNCaP-CS10, 5 × 103 cells/well) in 10% 
DCC-FBS medium. After overnight incubation, CH5137291 or bicalutamide at 
concentrations of 4.6 nM to 30 µM was added in the presence of R1881 (VCaP, 0.1 nM; 
LNCaP, 0.1 nM; LNCaP-BC2, 0.01 nM) or absence of R1881 (LNCaP-CS10). After an 
additional 10 days’ incubation, the number of remaining cells were estimated using a 
DNA quantity assay (FluoReporter Blue Fluorometric dsDNA Quantitation Kit; 
Invitrogen). 
 
Reporter gene assay of AR 
The following plasmids were used: GMLUC, an MMTV–luciferase reporter plasmid 
created by replacing the reporter of GMCAT (ATCC) with luciferase; phRL-CMV 
(Promega), a Renilla luciferase plasmid; and human AR expression plasmids 
corresponding to mutations (pcDNA3.1-hAR-WT, pcDNA3.1-hAR-W741C, and 
pcDNA3.1-hAR-T877A). 
Twenty-four hours before transfection, the PC3 cells in 10% DCC-FCS medium 
were plated onto 96-well plates at 1 × 104 cells/well. The cells were co-transfected with 
GMLUC (50 ng/well), phRL-CMV (0.5 ng/well), and human AR expression plasmid 
(10 ng/well) using a TransIT-Prostate Transfection Kit (Mirus, Madison, WI, USA). Six 
hours after the transfection, various doses of CH5137291 or bicalutamide were added in 
the presence of R1881 (WT, 0.05 nM; W741C, 0.5 nM; T877A, 0.5 nM) or absence of 
R1881. Cell lysates were collected 48 h after the treatment with the compounds, and the 
luciferase activity of each sample was measured using a Dual-Luciferase Reporter 
Assay System (Promega). 
 
Reporter gene assay of PR, GR, MR, and ERα 
Twenty-four hours before transfection, HeLa cells in 10% DCC-FBS medium were 
plated onto 96-well plates at 1 × 104 cells/well for the assays of PR and ERα. COS-7 
cells were plated at 0.75 × 103 cells/well for the assays of GR and MR. The cells were 
co-transfected with GMLUC (50 ng/well), phRL-CMV (0.5 ng/well), and expression 
plasmids of the nuclear receptors (10 ng/well of pSG5-hPR, pRShGR, or pRShMR) 
using Fugene 6 transfection reagent (Roche). For ERα, the cells were co-transfected 
with ERE-reporter vector (50 ng/well), phRL-CMV (0.5 ng/well), and ERα expression 
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vector HEG0 (1 ng/well) using Fugene 6 transfection reagent. Six hours after 
transfection, CH5137291 or bicalutamide (10 µM) were added in the presence or 
absence of the corresponding agonist (10 nM progesterone for PR, 10 nM 
dexamethasone for GR, 1 nM aldosterone for MR, and 1 nM estradiol for ERα). Cell 
lysates were collected 48 h after treatment with the compounds. Mifepristone (1 nM), 
mifepristone (10 nM), progesterone (10 nM), and fulvestrant (100 nM) were used as 
positive antagonists for PR, GR, MR, and ERα, respectively. 
 
Docking models analysis 
Models of CH5137291 docking with wild-type and W741C-mutant ARs were built 
based on the X-ray crystal structure of the W741L-mutant AR in complex with 
bicalutamide (Protein Data Bank accession code:1z95). The three-dimensional structure 
of CH5137291 was modeled using Sybyl software (Tripos Inc., St.Louis, USA) with a 
Tripos force field. 
In the docking model of CH5137291 for W741C-mutant AR, CH5137291 was 
manually docked to the W741C-mutant AR such that (i) the crystallographic structure 
of the W741C-mutant AR was fixed, (ii) helix 12 of the AR was removed from the AR 
model because of the intensive collision between CH5137291 and helix 12, (iii) the 
crystallographic structure of the trifluoromethyl benzonitrile moiety of bicalutamide and 
its binding mode were used for CH5137291 and kept fixed during the docking, (iv) the 
binding mode of the portion other than the trifluoromethyl benzonitrile moiety of 
CH5137291 was manually determined so as to avoid a steric collision between 
CH5137291 and the AR without helix 12, and (v) energy minimization of the 
“compound/AR without helix 12” complex was performed using a molecular mechanics 
method with the Tripos force field, on condition that the coordinates of AR without 
helix 12 were fixed. After the energy minimization, the crystallographic coordinates of 
helix 12 were re-built into the AR structure. 
The docking models of CH5137291 or bicalutamide for wild-type AR were built 
based on the docking model of CH5137291 or bicalutamide for W741C-mutant AR, 
respectively. C741 was changed to W741 such that the conformation of W741 of the 
model would be identical to that of the crystallographic structure of W741 of wild-type 
AR (PDB ID: 1e3g). 
 
Efficacy experiments in mouse xenograft models 
Xenograft models were prepared and plasma PSA was quantified as described 
previously (46). Briefly, LNCaP (2 × 106 cells), LNCaP-BC2 (2 × 106 cells), 
24 
 
LNCaP-CS10 (2 × 106 cells), or LuCaP35V (blocks of xenografted tumor) was 
subcutaneously inoculated into non-castrated or castrated 6- to 8-week-old male SCID 
mice. When the tumor size reached 90–400 mm3, the animals were randomized into 
control and treatment groups. The agents or vehicle (5% gum arabic; Sigma-Aldrich) 
were orally administered at 10 or 100 mg/kg once a day for 2–17 cycles of 5 days on/2 
days off starting from the day of randomization. The antitumor efficacy was evaluated 
by tumor volume (TV) and the percentage of tumor growth inhibition (TGI%). TV was 
estimated by using the equation V = ab2/2, where a and b are the length and width of the 
tumor, respectively. TGI% was calculated as follows: TGI% = [1 − (mean change in TV 
in each group treated with antitumor drugs/mean change in TV in control group)] × 100. 
The plasma PSA levels were measured by ELISA (Eiken Chemical, Tokyo, Japan). 
Relative PSA concentration (%) = (PSA concentration/PSA concentration on Day 0 of 
administration) × 100. Serum testosterone concentrations were measured using 
LC/MS/MS (ASKA Pharma Medical, Tokyo, Japan) at the end of the experiment. 
To evaluate the efficacy of CH5137291 on tumors that had become resistant to 
bicalutamide, LNCaP-xenografted non-castrated mice were orally administered 
bicalutamide (100 mg/kg) until resistant tumors appeared. The mice bearing resistant 
tumors were selected, re-randomized into two groups, and moved on to secondary 
treatment. Bicalutamide (100 mg/kg) was administered in one group and CH5137291 
(100 mg/kg) in the other group. The tumors with acquired resistance were defined as 
those that fulfilled both of the following two criteria: (1) (PSA concentration on Day 10 
of administration/PSA concentration on Day 0 of administration) × 100 < 85%, and 
(2) the tumor volume on the day of re-randomization/minimum tumor volume during 
primary treatment > 1.4. 
 
Exposure and serum PSA in cynomolgus monkeys 
For the exposure assay, the monkeys received a single oral administration of 
CH5137291 at doses of 0.1, 1, 10, or 100 mg/kg. The vehicle was 1% 
hydroxypropylcellulose (Nippon Soda, Tokyo, Japan). The serum concentration of 
CH5137291 was measured by using LC/MS/MS (API3200; Applied Biosystems, Foster 
City, CA, USA). To assess the effect of CH5137291 on serum PSA, I selected 4- to 
6-year-old monkeys with initial serum PSA concentrations of >0.25 ng/mL, as 
measured by using chemiluminescent immunoassay at BML, Inc. (Tokyo, Japan). The 
animals were randomized, and CH5137291 was orally administered daily for 7 days at 
doses of 0.1, 1, 10, or 100 mg/kg. Twenty-four hours after the last administration, serum 
was harvested and PSA concentration was measured. 
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Results 
 
Inhibition of AR nuclear translocation by CH5137291 
Kawata et al. (53) reported the inhibitory effect of CH5137291 on AR nuclear 
translocation by using COS-7 cells transiently transfected with human wild-type AR. In 
the present study, I examined the effect of CH5137291 on subcellular localization in 
prostate cancer cell lines with wild-type or mutated AR. For this purpose, I used LNCaP 
cells transfected with HaloTag-fused wild-type AR, W741C-mutant AR, or 
T877A-mutant AR. In each of these cells with three different types of AR, CH5137291 
clearly inhibited AR nuclear translocation in the presence of synthetic androgen R1881. 
In addition, CH5137291 in the absence of R1881 did not induce AR nuclear 
translocation suggesting that CH5137291 does not have an agonistic effect on AR 
(Fig. 6A). In contrast, bicalutamide did not inhibit AR nuclear translocation in the 
presence of R1881 and induced AR nuclear translocation in the absence of R1881. 
Next, I examined the effect of CH5137291, in comparison with bicalutamide, on the 
intracellular distribution of AR protein. For this purpose, LNCaP-CS10 cells were used, 
because AR in LNCaP-CS10 cells is androgen-independently activated. Bicalutamide 
reportedly acts as a full agonist on LNCaP-CS10 cells. I found that CH5137291 
decreased the nuclear AR level and increased the cytoplasmic AR level without 
affecting the total AR level (Fig. 6B). On the other hand, as was expected, bicalutamide 
increased the nuclear AR level but did not affect the total AR level. 
These results indicate that CH5137291 acts as an AR nuclear translocation inhibitor, 
not only in androgen-dependent prostate cancer cells with wild-type or mutant AR but 
also in androgen-independent prostate cancer cells having outlaw pathways. 
 
Cell growth inhibition by CH5137291 against hormone-sensitive prostate cancers 
and CRPCs in vitro 
The proliferation inhibitory activity of CH5137291, compared with bicalutamide, was 
examined in vitro using four prostate cancer cell lines (VCaP, LNCaP, LNCaP-BC2, 
and LNCaP-CS10) each with different hormone sensitivity and AR status (Table I, 
Fig. 7). The assays were all performed in the presence of optimal concentrations of 
synthetic androgen R1881 except for LNCaP-CS10, because LNCaP-CS10 does not 
require androgen for its proliferation. 
In VCaP cells, growth was completely inhibited by CH5137291 at concentrations of 
3 to 30 µM. In contrast, bicalutamide almost completely inhibited the cell growth at 
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3 µM, however at 30 µM, it induced cell growth. In LNCaP cells, CH5137291 inhibited 
cell growth more strongly than bicalutamide, and completely inhibited cell growth at 
concentrations of 1–30 µM. In LNCaP-BC2 cells, CH5137291 also showed stronger 
inhibition of cell growth than bicalutamide, and complete inhibition was observed at 
CH5137291 concentrations as low as 0.3 µM. Although bicalutamide showed strong 
inhibition of cell growth at 3 µM, cell growth was revived at higher concentrations. In 
LNCaP-CS10 cells, CH5137291 showed strong inhibition of cell growth, whereas 
bicalutamide enhanced cell growth. 
 
Antitumor activity of CH5137291 against CRPC xenografts 
The in vivo efficacy of CH5137291 on CRPCs was examined by using xenograft 
models of castrated SCID mice bearing LNCaP-BC2 and LNCaP-CS10. CH5137291 
treatment (10 and 100 mg/kg) potently inhibited tumor growth in both xenograft models. 
The TGI% in each model was as follows: LNCaP-BC2, 104% and 104% on Day 17 (at 
10 and 100 mg/kg CH5137291, respectively); LNCaP-CS10, 88% and 88% on Day 16 
(at 10 and 100 mg/kg CH5137291, respectively) (Fig. 8). The plasma PSA level was 
also measured as a pharmacodynamic biomarker of AR antagonist activity. In both of 
the xenograft models tested, CH5137291 completely inhibited the increase in plasma 
PSA level, even at the dose of 10 mg/kg, without agonistic activity (Fig. 8). In contrast, 
bicalutamide treatment (10 and 100 mg/kg) showed almost no or little effect on either 
TV or PSA level even at the dose of 100 mg/kg. 
 
Pure antagonistic effect of CH5137291 on the transcriptional activity of wild-type 
and mutant AR 
The antagonistic effect of CH5137291 on AR transcriptional activity was examined by 
reporter gene assay. For this purpose, PC3 cells transiently co-transfected with AR 
(wild-type, W741C, or T877A) expression vectors and GMLUC reporter vectors 
including an MMTV promoter, a well-characterized AR-targeting promoter, were used. 
The W741C and T877A mutations are known to cause resistance to bicalutamide and 
flutamide, respectively (19,22,32). 
In all of the three transfectants, CH5137291 inhibited transcriptional activity of AR 
in a dose-dependent manner in the presence of R1881 (Figs. 9A, B, C). Bicalutamide 
showed different behaviors in the three transfectants. With wild-type AR, bicalutamide 
showed dose-dependent inhibition in transcriptional activity up to 3 µM; however, 
resurgence was observed at higher bicalutamide concentrations (Fig. 9A). With 
W741C-mutant AR, bicalutamide had no inhibitory effect throughout the concentrations 
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used (Fig. 9B). With T877A-mutant AR, bicalutamide showed a weaker inhibitory 
effect compared with CH5137291. In the absence of R1881, CH5137291 showed no 
agonistic effect on the transcriptional activity of AR in any of the three transfectants 
(Figs. 9A, B, C). In contrast, bicalutamide strongly increased the transcriptional activity 
of W741C-mutant AR in a dose-dependent manner (Fig. 9B). With wild-type and 
T877A-mutant AR, bicalutamide increased the transcriptional activity at relatively high 
concentrations (Figs. 9A, C). 
 
Complete inhibition of helix 12 folding by CH5137291 in wild-type and 
W741C-mutant AR 
The folding of helix 12, present in the ligand-binding domain of AR, is reported to be 
necessary for a ligand-induced agonist effect on AR transcriptional activity (11,12). The 
crystal structure of the bicalutamide/W741C-mutant AR complex revealed that 
bicalutamide does not collide with the C741 of the AR as it does with W741 in the 
wild-type AR; therefore, helix 12 of the bicalutamide/W741C-mutant AR complex is 
folded in the same manner as when a ligand, such as R1881, binds to it (Fig. 10) (55). 
Reportedly, this is a reason for bicalutamide exhibiting an agonist effect in 
W741C-mutant AR. To investigate the differences in the mechanisms of CH5137291 
and bicalutamide with respect to agonist/antagonist effects against wild-type or 
W741C-mutant ARs, I examined a docking model of CH5137291 against wild-type and 
W741C-mutant ARs. The docking model indicated that the terminal sulfonamide group 
of CH5137291 intensively collided with the M895 residue of helix 12 in both the 
wild-type AR and W741C-mutant AR. The collision would cause a complete inhibition 
of helix 12 folding and would result in a pure antagonist effect in both wild-type and 
W741C-mutant ARs. The varying interactions between the compound and AR may lead 
to the differing agonist and antagonist characteristics of CH5137291 and bicalutamide, 
respectively, in wild-type and W741C-mutant ARs. 
 
Nuclear receptor specificity of CH5137291 
Because of the highly similar structures within the nuclear receptor superfamily, I used 
a reporter gene assay to profile the effect of CH5137291 on the transcriptional activity 
of other nuclear receptors, including PR, GR, MR, and ERα, in the presence or absence 
of ligands. CH5137291 exhibited weaker antagonistic effects on the PR as compared to 
bicalutamide. Moreover, it exhibited neither agonistic nor antagonistic effects on GR, 
MR, or ERα (Fig. 11). 
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Antitumor activity of CH5137291 in LuCaP35V xenografts that progressed after 
castration and in LNCaP xenografts that progressed during bicalutamide 
treatment 
The effects of CH5137291 was examined against LuCaP35V xenografted tumors that 
progressed in castrated mice and LNCaP xenografted tumors that had failed to respond 
to initial bicalutamide treatment. In the LuCaP35V xenograft model, CH5137291 
treatment (10 and 100 mg/kg) potently inhibited the tumor growth and plasma PSA 
level. The TGI% was 82% and 85% on Day 48 (at 10 and 100 mg/kg, respectively) 
(Fig. 12A). In contrast, bicalutamide treatment (10 and 100 mg/kg) showed almost no 
effect on TV or PSA level. In the LNCaP xenograft model, 50 days after initiation of 
bicalutamide treatment, animals with tumors that showed resistance to bicalutamide 
were selected and randomized into two groups. One group continued receiving 
bicalutamide and the other group was switched to CH5137291 treatment. Only in the 
group switched to CH5137291 treatment did the tumor growth become static and the 
plasma PSA level decrease (Fig. 12B). 
 
Long-term tumor growth inhibition by CH5137291 in the hormone-sensitive 
LNCaP xenograft model 
Long-term tumor growth inhibition against hormone-sensitive prostate cancer was 
examined by using an LNCaP xenograft in non-castrated SCID mice (Fig. 12C). The 
average time taken for the tumor volume to exceed double the initial volume was 113 
days in the CH5137291 group and 58 days in the bicalutamide group. In addition, 
CH5137291 suppressed the plasma PSA concentration and the reduction in body weight 
during the observation period. These results indicate that CH5137291 can control tumor 
growth of hormone-sensitive prostate cancer for nearly twice as long as the period of 
control with bicalutamide. 
 
Exposure of CH5137291 and serum PSA levels in cynomolgus monkeys 
Finally, to estimate the clinical therapeutic potential of CH5137291, cynomolgus 
monkeys were treated with CH5137291. Serum concentration of the drug and PSA as a 
pharmacodynamic biomarker was measured. The CH5137291 concentration 
dose-dependently increased. PSA concentration decreased in inverse proportion to the 
dosage of CH5137291 with a maximum 80% inhibition at 100 mg/kg (Fig. 13). 
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Discussion 
 
Three major AR-related mechanisms of castration resistance in prostate cancer have 
been reported: i) hypersensitivity to androgen caused by AR overexpression, ii) loss of 
ligand specificity due to AR mutation; and iii) androgen-independent activation of AR 
mediated by deregulated growth factors and cytokines (Fig. 1) (13). 
Following binding with androgen, AR exhibits transcriptional activity through 
dimerization, nuclear translocation, and binding to the androgen response element. Each 
of these processes is essential for AR signaling. Among these processes, My coworkers 
and I focused on the nuclear translocation, and screened for compounds that inhibited 
nuclear translocation of AR without agonistic activity, resulting in the finding of.a 
candidate: CH5137291. In the present study, I conducted a detailed investigation into 
the inhibitory activity of CH5137291 on nuclear translocation of AR. I found that 
CH5137291 inhibited—regardless of the presence of androgen—the nuclear 
translocation of wild-type, bicalutamide-resistant type (W741C), and flutamide-resistant 
type (T877A) ARs which were exogenously expressed in LNCaP cells. In contrast, 
bicalutamide induced the nuclear translocation of all of the above AR types, similar to 
the action of androgen (Fig. 6A). I also confirmed that CH5137291 inhibited the nuclear 
translocation of the AR that was endogenously expressed in LNCaP-CS10 (Fig. 6B). 
Because the nuclear translocation of AR is required for AR signaling in prostate 
cancer, it was considered that the inhibition of AR nuclear translocation was the most 
important characteristic of CH5137291.  
To investigate the importance of nuclear translocation of AR in the three 
mechanisms of castration resistance, I used CH5137291, an AR nuclear translocation 
inhibiting compound, and the following cells corresponding to each mechanism of 
resistance: i) LNCaP-BC2 cells as an AR overexpression model, ii) LNCaP-CS10 cells 
as an androgen-independent AR activation model, and iii) PC3 cells expressing mutant 
ARs for reporter gene assay as an AR mutation model. LNCaP-BC2 cells can 
proliferate at androgen concentrations as low as 1/10 of those required for parental 
LNCaP cells in vitro, and can grow in castrated male mice (46). LNCaP-CS10 cells 
proliferate AR-dependently in the absence of androgen in vitro, and can grow in 
castrated male mice. 
In in vitro studies, CH5137291 completely inhibited the cell growth of both 
LNCaP-BC2 and LNCaP-CS10 cells; however, bicalutamide showed a biphasic activity 
on the proliferation of LNCaP-BC2 cells, and surprisingly, it stimulated the 
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proliferation of LNCaP-CS10 cells even at the lower concentrations tested in vitro 
(Fig. 7B). In xenograft models of castrated mice with these cell lines, CH5137291 
showed significant antitumor activity along with a reduction in plasma PSA levels 
(Figs. 8A, B). In contrast, bicalutamide did not inhibit tumor growth at all in these 
xenograft models. These results coincide well with our previous reports (46), and 
suggest that CH5137291 will be effective on those castration resistant prostate cancers 
which have AR overexpression or androgen-independent activation of AR and do not 
respond to bicalutamide. 
The reporter gene assays performed using different types of mutant AR clearly 
showed that bicalutamide acts as a full agonist on the transcriptional activity in 
bicalutamide-resistant W741C-mutant AR, and as a partial agonist in wild-type AR and 
flutamide-resistant T877A-mutant AR (Figs. 9A, B, C) (19,22,32). In contrast, 
CH5137291 acted as a pure antagonist on the transcriptional activity in each of the ARs 
(Figs. 9A, B, C). These results suggest that CH5137291 is potentially superior to 
bicalutamide as an AR antagonist against all of the three mechanisms of castration 
resistance.  
Because the inhibition of AR nuclear translocation by CH5137291 induced the 
strong antitumor activity or anti AR transcriptional activity in CRPCs, it was considered 
that the nuclear translocation of AR is required for all three of the abovementioned 
mechanisms of castration resistance. 
To elucidate the pure AR antagonistic nature of CH5137291 in terms of 
three-dimensional structure, a docking model analysis was performed. The folding of 
helix 12 of AR is reported to be caused by ligand binding and is considered necessary 
for a ligand-induced AR agonist effect (11,12). The docking model revealed that 
CH5137291 intensively collided with the M895 residue of helix 12 in both wild-type 
AR and W741C-mutant AR (Fig. 10). This collision of CH5137291 would cause a 
complete inhibition of helix 12 folding and would result in a pure antagonist effect in 
both the wild-type AR and W741C-mutant AR. On the other hand, bicalutamide 
collided with the W741 residue in the wild-type AR, but did not collide with the C741 
residue in the W741C-mutant AR; subsequently, helix 12 of the 
bicalutamide/W741C-mutant AR complex was folded in the same manner as when the 
ligand binds to wild-type AR (55). This would be one of the reasons for the partial 
agonistic effect of bicalutamide in wild-type AR and its fully agonistic effect in 
W741C-mutant AR. 
I would like to take other step to discuss the AR nuclear translocation inhibiting 
compound as the therapeutic agent for CRPC. Recently, reports regarding the 
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development of the CYP17 inhibitor abiraterone acetate and the AR antagonist 
MDV3100 have described their efficacy against CRPC (51,56-58). My LNCaP-CS10 
xenograft study showed that abiraterone acetate did not exert an effect on CRPC with an 
androgen-independent AR activation mechanism of resistance because the mode of 
action of the agent is the inhibition of androgen synthesis, whereas LNCaP-CS10 
tumors grow in an androgen-independent manner (data not shown). MDV3100 is 
reported to have partial agonist activity on AR nuclear translocation (51); on the other 
hand, CH5137291 exhibited pure antagonist activity on AR nuclear translocation. These 
data suggest the advantages of CH5137291 over other agents against CRPCs. 
In addition to superior non-clinical efficacy, fewer adverse effects and higher 
exposure in humans are indispensable for the development of a compound for 
therapeutic use. Because AR belongs to the nuclear steroid receptor family and has a 
structure highly similar to that of other nuclear receptors (e.g., PR, GR, MR, and ERs), 
any drug targeting AR holds the possibility for cross reactivity-related adverse effects 
(59,60). My results indicated that CH5137291 exhibited weaker antagonistic effects on 
the PR as compared to bicalutamide and did not exhibit any agonist/antagonist effects 
on GR, MR, or ERα (Fig. 11A, B, C, D). I therefore consider that CH5137291 would 
not cause any adverse events through cross reactivity with other nuclear receptors. 
I also examined the effectiveness of CH5137291 in various therapeutic situations. 
To mimic second-line hormonal therapy, I used a castration-resistant LuCaP35V and 
LNCaP xenograft models (54). In the latter model, treatment was changed to 
CH5137291 when the tumor became resistant to bicalutamide after initial tumor growth 
inhibition by bicalutamide. CH5137291 showed antitumor activity against both of the 
two models (Fig. 12A, B). To mimic first-line hormonal therapy, the duration of tumor 
stabilization in the LNCaP xenograft model was examined. CH5137291 showed 
long-term antitumor efficacy as compared to bicalutamide (Fig. 12C). These results 
suggest that CH5137291 was potentially efficacious not only against CRPCs that 
progress despite castration or bicalutamide treatment but also against hormone 
therapy-naïve prostate cancers. 
Concerning exposure, other pure AR antagonists such as CH4892280 have failed to 
achieve adequate plasma levels due to their metabolic instability (11,45). However, 
based on the present results, sufficient exposure of CH5137291 is expected in humans 
by virtue of its remarkable stability in the liver microsomes of mice, rats, monkeys, and 
humans ((53) and data not shown) as well as the dose-dependent increase in levels in 
plasma/serum, which were adequately efficacious not only in mice xenografts but also 
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in cynomolgus monkeys (Fig. 13). These results suggest that CH5137291 shows 
promising clinical efficacy. 
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General discussion 
 
Three mechanisms of castration resistance have been suggested to date: i) 
overexpression of AR, ii) mutation of AR, and iii) androgen-independent AR activation 
(13). Since several cell line models have already been established for investigating 
mechanisms i) and ii) (17,22,30-32), they have been widely proven with molecular and 
cellular biological analyses (15-22). However, mechanism iii) has not been extensively 
analyzed in a molecular/cellular biological framework because of the lack of an 
appropriate cell line model, and thus has not yet been clearly proven.  
Nuclear translocation of AR is considered to be a common signaling pathway in 
HSPC as well as in these three CRPCs. Therefore, I hypothesized and investigated that 
inhibition of AR nuclear translocation would inhibit the proliferation of all three types 
of CRPC, and investigated the significance of AR nuclear translocation in CRPCs with 
the above three major mechanisms.  
Prior to starting the investigation, I tried to establish a CRPC cell line with the 
mechanism of androgen-independent AR activation, which had not been experimentally 
explored in detail previously. The LNCaP-CS10 cell line was established by culturing 
the HSPC cell line LNCaP in a medium supplemented with 10% FBS from which the 
steroid hormone was removed and 10 μM of bicalutamide for 4 months. In 
LNCaP-CS10, cell proliferation and PSA expression increased in the absence of 
androgen, although AR overexpression and additional mutation were not observed. In 
the in vivo LNCaP-CS10 xenograft model, the same growth rate was observed under 
non-castration conditions and castration conditions, and inhibition of tumor growth and 
PSA expression was not observed when bicalutamide or abiraterone, testosterone 
synthesis inhibitor, was administered. In addition, LNCaP-CS10 showed suppressed 
proliferation and PSA expression when AR was knocked down by siRNA. These data 
indicated that LNCaP-CS10 was a CRPC cell line with a mechanism of 
androgen-independent AR activation. Since the mechanism of androgen-independent 
AR nuclear translocation in LNCaP-CS10 cells has not been elucidated, further detailed 
analysis is required. 
Next, to investigate the influence of blocking AR activity through inhibition of AR 
nuclear translocation in CRPC, my collaborators and I developed the compound 
CH5137291, which inhibits the AR nuclear translocation. CH5137291 was screened 
from 2000 compounds based on the inhibitory effects of wild-type and mutant AR 
transcription activity, AR nuclear translocation, and proliferation of CRPC cells, and 
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observation of a conformational change of AR through modeling as indicators (52,53). 
In this study, I used the LNCaP-BC2 cell line as an AR-overexpression model, the PC3 
cell line in which W741C or T877A mutant AR was transiently transfected as an AR 
mutation model, and the LNCaP-CS10 cell line as an androgen-independent AR 
activation model (46). 
In LNCaP-CS10 cells, CH5137291 more strongly suppressed the nuclear 
translocation of endogenous AR, cell proliferation in vitro, tumor growth, and PSA 
expression in vivo compared to bicalutamide. Furthermore, CH5137291 strongly 
inhibited the nuclear translocation and transcriptional activity of W741C or T877A 
mutant AR, which causes castration resistance, and of wild-type AR. 
Androgen-dependent AR transcriptional activation is caused by the helix 12 folding of 
AR (11,12). According to the docking model analysis, CH5137291 is suggested to 
compete with androgen for binding, which inhibits the helix 12 folding of AR by 
immediate interference with the M895 residue both in the wild-type AR and in the 
W741C mutant AR. In addition, CH5137291 inhibited tumor growth and PSA 
expression in vivo against the AR-overexpressing LNCaP-BC2 cell line. Based on these 
findings, it was shown that tumor proliferation is strongly suppressed when AR 
transcriptional activity is completely blocked by inhibition of AR nuclear translocation 
in CRPC models with the above-mentioned three mechanisms. 
In addition to its superior non-clinical efficacy, CH5137291 was suggested to have no 
adverse effects, because it exhibited weaker antagonistic effects on PR as compared to 
bicalutamide and did not exhibit any agonist/antagonist effects on GR, MR, or ERα. The 
lack of side effects associated with cross-reactivity to these nuclear receptors is an 
important feature of CH5137291 in therapeutic applications (59,60). 
Finally, to predict the effect of the AR nuclear translocation inhibitor CH5137291 in 
clinical prostate cancer, the following tests were conducted. First, to investigate its 
potential in secondary therapy, I investigated the effect of CH5137291 on tumor 
re-growth after administration of bicalutamide using the in vivo LNCaP xenograft model. 
As a result, tumor regrowth was strongly suppressed. Next, to examine its potential in 
primary therapy, the effect of CH5137291 on LNCaP tumors was examined, and it was 
found that the response period was approximately twice as long as that of bicalutamide. 
In conclusion, I established the first cell model of the mechanism of 
androgen-independent AR activation in CRPC with establishment of the LNCaP-CS10 
cell line. Thereby, it was demonstrated that castration resistance was acquired by 
androgen-independent AR activation, which is the first experimental demonstration of 
this mechanism (Chapter I). Inhibition of AR nuclear translocation is suggested to 
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exhibit not only a stronger therapeutic efficacy against CRPCs with AR overexpression, 
AR mutation, and androgen-independent AR activation as the primary mechanisms of 
resistance but also against HSPC (Chapter II). I expect that CH5137291 will be further 
developed in novel therapeutic approaches for prostate cancer.  
Besides its effects in prostate cancer, the approach suggested in the present study is 
expected to also have applications in breast cancer with hormone receptor-dependent 
proliferation by specifically inhibiting the nuclear translocation of hormone receptors 
and completely blocking their transcriptional activity. This strategy may exhibit not only 
a stronger therapeutic efficacy against hormone deprivation therapy-resistant cancers 
but could also prolong the duration of response to hormone depletion therapy-sensitive 
cancers. 
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Model 
Hormone sensitive or 
Castration resistant 
AR status AR mutation 
VCaP Hormone sensitive Benchmark Wild-type 
LNCaP Hormone sensitive Benchmark T877A 
LNCaP-BC2 Castration resistant AR overexpression T877A 
LNCaP-CS10 Castration resistant 
Androgen-independent 
activation of AR 
T877A 
LuCaP35V Castration resistant Unknown Wild-type 
 
 
Table I. 
Castration-resistant prostate cancer models. 
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Figure 1. 
Mechanisms of castration resistance. i) hypersensitivity to androgen due to 
overexpression of AR, ii) loss of ligand specificity following an AR mutation, iii) and 
androgen-independent activation of AR mediated by deregulated growth factors and 
cytokines. 
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Figure 2.  
Effects of androgen and bicalutamide on growth, PSA production, nuclear localization 
of AR in LNCaP-CS10 cells. (A) Cell growth of LNCaP and LNCaP-CS10 cells was 
analyzed in the presence of R1881 after 9 days of treatment. (B) Intracellular PSA 
levels of LNCaP and LNCaP-CS10 cells were measured in the presence of R1881. (C) 
Cell growth of LNCaP and LNCaP-CS10 cells was analyzed in the presence of 
bicalutamide after 9 days of treatment. (D) Intracellular PSA levels of LNCaP and 
LNCaP-CS10 cells were measured in the presence of bicalutamide. All data are 
expressed as the mean + SD of triplicate determinations. (E) Nuclear localization and 
expression of AR were determined by Western blotting of AR against nuclear and total 
fractions, respectively, prepared from LNCaP and LNCaP-CS10 cells in the presence or 
absence of bicalutamide. 
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Figure 3.  
Effects of AR siRNA on androgen-independent growth of LNCaP-CS10 cells. (A) 
LNCaP cells were transiently transfected with two AR siRNAs or scramble siRNA. 
Intracellular AR protein levels were determined by ELISA and are expressed as the 
percentage of the control (non-siRNA). (B) LNCaP-CS10 cells were transiently 
transfected with two AR siRNAs or scramble siRNA. Intracellular AR protein levels 
were determined by ELISA and are expressed as the percentage of the control 
(non-siRNA). (C) LNCaP cells were transiently transfected with two AR siRNAs or 
scramble siRNA. Cell count on day 0 and day 6 after transfection was measured and 
growth is expressed as the percentage of day 0. (D) LNCaP-CS10 cells were transiently 
transfected with two AR siRNAs or scramble siRNA. Cell count on day 0 and day 6 
after transfection was measured and growth is expressed as the percentage of day 0. (E) 
LNCaP cells were transiently transfected with two AR siRNAs or scramble siRNA. 
Intracellular PSA levels were determined by ELISA. (F) LNCaP-CS10 cells were 
transiently transfected with two AR siRNAs or scramble siRNA. Intracellular PSA 
levels were determined by ELISA. All data are expressed as the mean ± SD of the 
triplicate determinations.  
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Figure 4.  
Tumorigenicity of LNCaP-CS10 in non-castrated and castrated SCID mice. (A) LNCaP 
cells were inoculated into non-castrated and castrated male SCID mice (n = 10/group) 
and the mice with palpable tumors (>50mm3) were scored. (B) LNCaP-CS10 cells were 
inoculated into non-castrated and castrated male SCID mice (n = 10/group) and the 
mice with palpable tumors (>50mm3) were scored. (C) LNCaP cells were inoculated 
into non-castrated and castrated male SCID mice (n = 10/group) and the tumors were 
measured.  (D) LNCaP-CS10 cells were inoculated into non-castrated and castrated 
male SCID mice (n = 10/group) and the tumors were measured. All data represent the 
mean ± SE (C and D). 
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Figure 5.  
Effect of bicalutamide on growth of LNCaP-CS10 xenograft tumors and serum PSA 
levels in castrated male SCID mice. (A) LNCaP cells were inoculated into non-castrated 
male SCID mice. The tumor-bearing mice were orally administered bicalutamide (0, 10, 
100 mg/kg) or castrated (n = 5/group) with administration of the drug for five cycles of 
5 days on, 2 days off. Tumor size was measured. (B) LNCaP-CS10 cells were 
inoculated into castrated male SCID mice. The tumor-bearing mice were orally 
administered bicalutamide (0, 10, 100mg/kg, n = 5/group) with administration for four 
cycles of 5 days on, 2 days off. Tumor size was measured. (C) LNCaP cells were 
inoculated into non-castrated male SCID mice. The tumor-bearing mice were orally 
administered bicalutamide (0, 10, 100 mg/kg) or castrated (n = 5/group) with 
administration of the drug for five cycles of 5 days on, 2 days off. Serum PSA levels 
were measured. (D) LNCaP-CS10 cells were inoculated into castrated male SCID mice. 
The tumor-bearing mice were orally administered bicalutamide (0, 10, 100mg/kg, n = 
5/group) with administration for four cycles of 5 days on, 2 days off. Serum PSA levels 
were measured. All data represent the mean ± SE.  
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Figure 6. 
Effect of CH5137291 on subcellular localization of wild-type and mutant AR. 
(A) Antagonist/agonist effects of CH5137291 and bicalutamide (10 µM) on AR 
subcellular localization. HaloTag fused with wild-type AR, W741C-mutant AR, or 
T877A-mutant AR and transiently transfected into LNCaP cells was visualized after 2 h 
of treatment with CH5137291 or bicalutamide in the presence (0.5 nM) or absence of 
R1881. Scale bars: 10 µm. (B) Effects of CH5137291 and bicalutamide (10 µM) on AR 
protein levels in nuclear, cytoplasmic, and total fractions of LNCaP-CS10 cells as 
determined by western blotting in the absence of R1881. 
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Figure 7. 
Growth inhibition of human prostate cancer cells by CH5137291 in vitro. Inhibition 
effects of CH5137291 and bicalutamide on VCaP, LNCaP, LNCaP-BC2, and 
LNCaP-CS10 cell growth were examined in the presence or absence of R1881 (0.1 nM 
for VCaP; 0.1 nM for LNCaP; 0.01 nM for LNCaP-BC2; 0 nM for LNCaP-CS10). 
Living cells on Day 0 are shown by a dotted line. Data represent the mean ± SD of 
triplicate determinations. 
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Figure 8. 
Antitumor activity of CH5137291 and plasma PSA levels in LNCaP-BC2 and 
LNCaP-CS10 xenograft models. (A) Effects of CH5137291 and bicalutamide (10 and 
100 mg/kg) on tumor volume and plasma PSA levels of LNCaP-BC2 xenografts in 
castrated mice. (B) Similar experiments using LNCaP-CS10 xenografts in castrated 
mice. Data represent the mean ± SE (A, n = 4; B, n = 5). 
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Figure 9. 
Effect of CH5137291 on the transcriptional activity of wild-type AR and mutant AR. 
(A–C) The antagonist effect of CH5137291 and bicalutamide on AR transcriptional 
activity of PC3 cells transiently co-transfected with a reporter vector and the expression 
vector of wild-type AR (A), W741C-mutant AR (B), or T877A-mutant AR (C) was 
analyzed in the presence of R1881 (0.05 nM for wild-type; 0.5 nM for W741C and 
T877A). The agonist effect of CH5137291 and bicalutamide was analyzed in the 
absence of R1881. Data are expressed as a percentage of control (100%: agent is 0 µM 
and R1881 is as described above; 0%: agent and R1881 are both absent) and the mean ± 
SD of triplicate determinations. 
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Figure 10. 
Docking model of CH5137291 (left) and bicalutamide (right) for wild-type AR (upper) 
and W741C-mutant AR (lower). W741 residue of wild-type AR (white), C741 residue 
of W741C-mutant AR (white), M895 residue of wild-type/W741C-mutant AR (salmon 
pink), CH5137291 (cyan), and bicalutamide (faint pink) are depicted in stick form. 
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Figure 11. 
Nuclear receptor specificity of CH5137291. (A–D) Agonist/antagonist effects of 
CH5137291 and bicalutamide on the transcriptional activity of PR (A), GR (B), MR (C), 
and ERα (D). Data are expressed as mean + SD of triplicate determinations. 
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Figure 12. 
Antitumor activity of CH5137291 and plasma PSA levels in LuCaP35V and LNCaP 
xenograft models. (A) Effects of CH5137291 and bicalutamide (10 and 100 mg/kg) on 
tumor volume and plasma PSA levels of LuCaP35V xenografts in castrated mice. (B) 
Effects of switching agent from bicalutamide to CH5137291 on tumor volume and 
plasma PSA levels. LNCaP tumor-bearing non-castrated mice (n = 25) were 
administered bicalutamide (100 mg/kg) until a resistant tumor appeared (n = 17). The 
animals were then randomized and the agent was continued (▲) or switched from 
bicalutamide to CH5137291 (100 mg/kg) (■). (C) Long-term effects of CH5137291, 
bicalutamide (100 mg/kg), or castration on tumor volume, plasma PSA levels, and body 
weight of the LNCaP xenograft model in non-castrated mice. All data represent the 
mean ± SE (n = 5). 
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Figure 13. 
Dose-dependent exposure of CH5137291 and serum PSA levels in cynomolgus 
monkeys. (A) Analysis of the exposure of orally administered single doses of 
CH5137291 (0.1, 1, 10, and 100 mg/kg) in male monkeys. Data are expressed as mean 
± SE (n = 3). (B) Serum PSA levels after 7 days of daily administration of CH5137291 
(0.1, 1, 10, and 100 mg/kg) in non-castrated male monkeys (n = 3). Antagonist activity 
was determined by the relative PSA concentration normalized to the value on Day 0. 
Data are expressed as mean + SE. 
 
